Buparlisib (BKM120)

For research use only. Not for use in humans.

目录号:S2247 别名: NVP-BKM120

Buparlisib (BKM120) Chemical Structure

Molecular Weight(MW): 410.39

Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。

规格 价格 库存 购买数量  
10mM (1mL in DMSO) RMB 2227.95 现货
RMB 1400.12 现货
RMB 2607.65 现货
RMB 7928.28 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用Selleck生产的Buparlisib (BKM120)发表文献153篇:

产品安全说明书

PI3K抑制剂选择性比较

生物活性

产品描述 Buparlisib (BKM120, NVP-BKM120) 是一种选择性 PI3K 抑制剂,在无细胞试验中作用于p110α/β/δ/γIC50分别为 52 nM/166 nM/116 nM/262 nM。对 VPS34,mTOR,DNAPK 的作用效果下降,而对 PI4Kβ几乎没有活性。Buparlisib 可诱导凋亡。Phase 2。
特性 BKM120是可用于口服的生物有效的PI3K抑制剂。
靶点
p110α [1]
(Cell-free assay)
p110δ [1]
(Cell-free assay)
p110β [1]
(Cell-free assay)
p110γ [1]
(Cell-free assay)
Vps34 [1]
(Cell-free assay)
52 nM 116 nM 166 nM 262 nM 2.4 μM
体外研究

BKM120作用于解除PI3K调节的细胞系,包括A2780, U87MG, MCF7和DU145时,具有抗增殖活性,GI50为0.1-0.7 nM。[1] BKM120诱导多发性骨髓瘤细胞(ARP1, ARK, MM.1S, MM1.R和U266)凋亡,导致G1期细胞增多,S期细胞减少。BKM120诱导CD138+原代MM 细胞凋亡,且作用于CD138−基质细胞时毒性较低。BKM120可引起BimS的上调和XIAP的下调。[2]BKM120作用于人类胃癌细胞系,降低mTOR下游信号,具有抗增殖活性。BKM120作用于KRAS突变的胃癌细胞系,可以增强p-ERK或 p-STAT3。BKM120 和STAT3阻断剂联用, 作用于含突变KRAS的细胞,诱导凋亡,具有协同效应,但是作用于KRAS野生型细胞没有这种效果。[3]BKM120主要通过Aurora B激酶调节有丝分裂崩坏。[4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 MUDDfZRwfG:6aXOgRZN{[Xl? MYW3NkBp NGThTmVFVVOR M2XjemN6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJG1ETjdiY3XscJMh\XiycnXzd4lv\yCSSUPLZYxxcGFiRUW0OWshdXW2YX70JJdqfGhiR1m1NEBw\iByLkCwNFE2QCEQvF2= NXOyNFlZOjR7MECyOlY>
DU145 MWDDfZRwfG:6aXOgRZN{[Xl? MoHlO|IhcA>? MVPEUXNQ NW\nb3RIS3m2b4TvfIlkcXS7IHHnZYlve3RiaIXtZY4hTFVzNEWgZ4VtdHNiZYjwdoV{e2mwZzDMT2IyKG23dHHueEB4cXSqIFfJOVAhd2ZiMD6wNFA1OzVizszN MlTjNlQ6ODB{Nk[=
A2780 M2rsNGN6fG:2b4jpZ{BCe3OjeR?= MoPEO|IhcA>? NIfnZllFVVOR NYHaUGhuS3m2b4TvfIlkcXS7IHHnZYlve3RiUGTFUk1l\W[rY3nlcpQhcHWvYX6gRVI4QDBiY3XscJMhf2m2aDDHTVUxKG:oIECuNFAxPjN3IN88US=> NGL3d4czPDlyMEK2Oi=>
U87MG NEH0Z5FEgXSxdH;4bYMhSXO|YYm= NXz3cVhsPzJiaB?= MnvWSG1UVw>? MkTmR5l1d3SxeHnjbZR6KGGpYXnud5QhWFSHTj3k[YZq[2mnboSgbJVu[W5iVUi3UWch[2WubIOge4l1cCCJSUWwJI9nKDBwMECwOlk5KM7:TR?= MVGyOFkxODJ4Nh?=
A2780 MlT0SpVv[3Srb36gRZN{[Xl? M4TDNVEhcA>? MX7EUXNQ MkLrTY5pcWKrdHnvckBw\iCSSUPLMY1m\GmjdHXkJGFMXCCVZYK0O|MheGixc4Doc5J6dGG2aX;uJJdqfGhiRVO1NEBw\iByLkC1OUDPxE1? M3PMXVI1QTByMk[2
DU145 MUDGeY5kfGmxbjDBd5NigQ>? M1v3XVEhcA>? MnXVSG1UVw>? NYPncHBLUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIHj1cYFvKESXMUS1JINmdGy|IHjhdoJwemmwZzDMT2IyKG23dHH0bY9vKHerdHigSWM2OCCxZjCwMlA4OyEQvF2= MnzzNlQ6ODB{Nk[=
A2780 NGTscIhHfW6ldHnvckBCe3OjeR?= MVqxJIg> NILJOmpFVVOR M2TU[mlvcGmkaYTpc44hd2ZiUFmzT{1u\WSrYYTl[EBCU1RiU3XyOFc{KHCqb4PwbI9zgWyjdHnvckBqdiCSVFXOMYRm\mmlaXXueEBpfW2jbjDBNlc5OCClZXzsd{B4cXSqIFXDOVAhd2ZiMD6wO|Qh|ryP NX7HV3k3OjR7MECyOlY>
MCF7 NXW4O4Q2TnWwY4Tpc44hSXO|YYm= NUDXVWd3OSCq Mn;xSG1UVw>? MYLJcohq[mm2aX;uJI9nKFCLM1vhcJBp[SCHNUS1T{BufXSjboStcYVlcWG2ZXSgRWtVKFOnckS3N{BxcG:|cHjvdplt[XSrb36ge4l1cCCHQ{WwJI9nKDBwMTFOwG0> MVqyOFkxODJ4Nh?=
U87MG M1nYOGZ2dmO2aX;uJGF{e2G7 Mln2NUBp MXXEUXNQ NWDZ[ItSUW6qaXLpeIlwdiCxZjDQTVNMNW2nZHnheIVlKEGNVDDT[ZI1PzNicHjvd5Bpd3K7bHH0bY9vKGmwIGDUSW4u\GWoaXPp[Y51KGi3bXHuJHU5P02JIHPlcIx{KHerdHigSWM2OCCxZjCwMlE{KM7:TR?= NYLzdmpuOjR7MECyOlY>
A2780 MmK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXQbWdLPzJiaB?= NX\1fIU5TE2VTx?= MkXLSWM2OD1yLkWyJO69VQ>? M{HOTFI1QTByMk[2
SKMES-1 NUnO[GtMS3m2b4TvfIlkKEG|c3H5 MVmxJO69VQ>? MX:3NkBp NXTQbFYxUW6mdXPld{Bk\WyuIHTlZZRp MojLNlYxOTN|MUi=
H596 NFe3dZVHfW6ldHnvckBCe3OjeR?= NHrI[JkyKM7:TR?= NFvPfJJKdXCjaYLzJINmdGxibXnndoF1cW:w Ml23NlYxOTN|MUi=
HCC2450 M4DNXmZ2dmO2aX;uJGF{e2G7 NUn1U2E4OSEQvF2= MXjJcZBicXK|IHPlcIwhcW64YYPpc44> MYiyOlAyOzNzOB?=
A549 NGfofHZHfW6ldHnvckBCe3OjeR?= NFvXTo42ODBibl2= MnPpOFghcA>? Mni1SG1UVw>? MXzJcohq[mm2czDBb5Qh[WO2aY\heIlwdg>? MlLrNlU6Ozd{OUm=
A549 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\FXlM1OSEQvF2= MYi3NkBp NGSzWo5FVVOR M2LXdWlvcGmkaYTzJINmdGxiZ4Lve5Rp MWmyOVk{PzJ7OR?=
H522 NYjDXVFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7QcmF7OSEQvF2= M2[5c|czKGh? MnPFSG1UVw>? M{DzNmlvcGmkaYTzJINmdGxiZ4Lve5Rp M4ryS|I2QTN5Mkm5
LNCaP Mk\SSpVv[3Srb36gRZN{[Xl? NFjFWHcyKM7:TR?= Mor3V5VxeHKnc4Pld{BxNUGNVDDs[ZZmdHN? Ml[2NlU{PjB5OUm=
LNCaP95 NUDyO5gxTnWwY4Tpc44hSXO|YYm= M2roOlEh|ryP M3jBWXN2eHC{ZYPz[ZMheC2DS2SgcIV3\Wy| NFjR[nUzPTN4MEe5PS=>
HCT-15 NXTuUGNISXCxdH;zbZMhSXO|YYm= M37vV|ExKM7:TR?= MV60PEBp NULNU402TE2VTx?= MWPJcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUWgZ4VtdHNiaHHyZo92emmwZzDQTWs{S0FiaH;0d5BwfCCvdYTheIlwdg>? M4\NZlI2OTV{MkS1
HCT-116 Mk\kRZBwfG:|aYOgRZN{[Xl? MnLYNVAh|ryP MX:0PEBp NVPlb|VqTE2VTx?= MX7JcoR2[2W|IHHwc5B1d3OrczDpckBJS1RvMUG2JINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NUTIcFlUOjVzNUKyOFU>
NCI-H460 Mly4RZBwfG:|aYOgRZN{[Xl? NW\BSYN3OTBizszN NVzGcIpEPDhiaB?= NV\McJU5TE2VTx?= NIL4No5KdmS3Y3XzJIFxd3C2b4Ppd{BqdiCQQ1mtTFQ3OCClZXzsd{Bp[XKkb4XybY5oKFCLS{PDRUBpd3S|cH;0JI12fGG2aX;u NH:2XJczPTF3MkK0OS=>
SKOV-3 NIHBRXlCeG:2b4Ppd{BCe3OjeR?= Mnn1NVAh|ryP MXu0PEBp NXPoVWZpTE2VTx?= MnzsTY5lfWOnczDhdI9xfG:|aYOgbY4hW0uRVj2zJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? MnPHNlUyPTJ{NEW=
BSY-1 MXXBdI91d3OrczDBd5NigQ>? Mn;5NVAh|ryP MoLnOFghcA>? M1;CN2ROW09? M1;KWWlv\HWlZYOgZZBweHSxc3nzJIlvKEKVWT2xJINmdGy|IHjhdoJwfXKrbnegVGlMO0ODIHjveJNxd3RibYX0ZZRqd25? NVPJNo9DOjVzNUKyOFU>
MKN-1 NH3iOY1CeG:2b4Ppd{BCe3OjeR?= MnH4NVAh|ryP MmDmOFghcA>? NYnj[mdQTE2VTx?= NX\icoQzUW6mdXPld{BieG:ydH;zbZMhcW5iTVvOMVEh[2WubIOgbIFz[m:3cnnu[{BRUUt|Q1GgbI91e3CxdDDteZRifGmxbh?= MVWyOVE2OjJ2NR?=
NCI-H522 NXnQWHl4SXCxdH;zbZMhSXO|YYm= NGjHTGcyOCEQvF2= NFXOSHM1QCCq MWrEUXNQ MYXJcoR2[2W|IHHwc5B1d3Orcx?= Mnn4NlUyPTJ{NEW=
OVCAR-3 NIfubZVCeG:2b4Ppd{BCe3OjeR?= NYjD[nkxOTBizszN NYrQeItsPDhiaB?= MXrEUXNQ M3PhZmlv\HWlZYOgZZBweHSxc3nz NYT3VINHOjVzNUKyOFU>
HBC-5 NUSyVGxkSXCxdH;zbZMhSXO|YYm= MUCxNEDPxE1? M2XlN|Q5KGh? MlT5SG1UVw>? MlvaTY5lfWOnczDhdI9xfG:|aYO= MljONlUyPTJ{NEW=
RXF-631L NXXBTmhqSXCxdH;zbZMhSXO|YYm= MV:xNEDPxE1? M{TnfVQ5KGh? NILKbW9FVVOR Mn3aTY5lfWOnczDhdI9xfG:|aYO= NEfCXVYzPTF3MkK0OS=>
MKN-45 NFrUb5FCeG:2b4Ppd{BCe3OjeR?= Mnv6NVAh|ryP NGXnW4I1QCCq M{OyTWROW09? MXXJcoR2[2W|IHHwc5B1d3Orcx?= NF\hZ3AzPTF3MkK0OS=>
BON-1 MlLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn3ZOVAxKG6P M3rBTlExKGR? MYrEUXNQ MmLHTY5pcWKrdIOgZ4VtdCCpcn;3eIg> M3\KdlI2ODJ4Mkmy
BON-1 NX:wS5pQTnWwY4Tpc44hSXO|YYm= M{D6VVUxOCCwTR?= Mon2OEBp NX\Pc3pQTE2VTx?= MnjnTY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= MX2yOVAzPjJ7Mh?=
QGP-1 NEHLbFlHfW6ldHnvckBCe3OjeR?= NHnsWGs2ODBibl2= MWG0JIg> NHvWeG9FVVOR Ml73TY5pcWKrdIOgdIhwe3Cqb4L5cIF1cW:wIH;mJGFMXCCjdDDUbJI{ODhiYX7kJHNmejR5Mx?= NFnoS2UzPTB{NkK5Ni=>
Huh7 NIfsT|VHfW6ldHnvckBCe3OjeR?= MXixJO69VQ>? M2HB[lEhcA>? NV[5bpozTE2VTx?= MVrJcohq[mm2czDwbI9{eGixconsZZRqd25ib3[gRWtVKGG2IGPldlQ4PA>? NHfTUIwzPTByNESwNy=>
BNL NWfIbJFSTnWwY4Tpc44hSXO|YYm= MoPUNUDPxE1? Mo\5NUBp MonZSG1UVw>? M4LORWlvcGmkaYTzJJBpd3OyaH;yfYxifGmxbjDv[kBUPg>? M1fGXFI2ODB2NECz
MDA-MB-175 M4jMUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzM[mhMOSEQvF2= NGDKemg2KGR? NGTZ[FVFVVOR NFHn[4dKSzVyPEGg{txO MnvpNlQ5Pzl5OU[=
MDA-MB-134 M3jZSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXj0SIdTOSEQvF2= MoGyOUBl NGHicYJFVVOR MUfJR|UxRDFizszN NF63WY0zPDh5OUe5Oi=>
HCC1500 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILY[FQyKM7:TR?= Mm[3OUBl NV;TVYFFTE2VTx?= NI[x[G9KSzVyPEGg{txO MXOyOFg4QTd7Nh?=
EFM-19 Mk\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVKxJO69VQ>? NUfpPXV5PSCm MYrEUXNQ MYTJR|UxRDFizszN MYGyOFg4QTd7Nh?=
ZR-75-30 M4HFfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLxNUDPxE1? M2f1dlUh\A>? NWfwXnFLTE2VTx?= M3zL[mlEPTB:MTFOwG0> MnLGNlQ5Pzl5OU[=
MDA-MB-361 M2TuTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWWxJO69VQ>? MmjiOUBl M1HLd2ROW09? M3mxdWlEPTB:MTFOwG0> MnvqNlQ5Pzl5OU[=
T-47D MoPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWGxJO69VQ>? NI\KOmw2KGR? NU\YTmw3TE2VTx?= M1TMTGlEPTB:MTFOwG0> MXSyOFg4QTd7Nh?=
SK-BR-3 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4HnR|Eh|ryP M3LGPVUh\A>? Ml;DSG1UVw>? M3fZTWlEPTB:MTFOwG0> NXi3WmVPOjR6N{m3PVY>
UACC-732 M1HhSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NE[wXpoyKM7:TR?= MmHOOUBl NWjvV4lwTE2VTx?= NGXjc5hKSzVyPEGg{txO NXnFXmZkOjR6N{m3PVY>
BT-474 NUH6VXdQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYSxJO69VQ>? NIC5NI02KGR? MkDxSG1UVw>? NX\rUW91UUN3MEyxJO69VQ>? MnPqNlQ5Pzl5OU[=
HCC202 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnnZ24yKM7:TR?= NW[zU|RHPSCm NXjVTZRNTE2VTx?= MnfUTWM2ODxzIN88US=> NGe0T4wzPDh5OUe5Oi=>
MCF7 M3LPc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PyNFEh|ryP MWK1JIQ> MXLEUXNQ M2\JWGlEPTB:MTFOwG0> NV[1cIlUOjR6N{m3PVY>
MDA-MB-415 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTGNUDPxE1? NEC1Sm82KGR? MlK1SG1UVw>? NV\k[lZLUUN3MEyxJO69VQ>? NUPMZWloOjR6N{m3PVY>
MDA-MB-453 NXe1VYc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYnGdZM6OSEQvF2= MnLLOUBl NXTZPVlNTE2VTx?= NEHCdY1KSzVyPEGg{txO NYfSN|FYOjR6N{m3PVY>
ZR-75-1 NFPqTZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGS4PIIyKM7:TR?= MXq1JIQ> MXLEUXNQ MWjJR|UxRDFizszN MlP0NlQ5Pzl5OU[=
HCC38 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWjjZ3JSOSEQvF2= NWDa[op3PSCm NEDLO2JFVVOR MWnJR|UxRDFizszN M{PZRlI1QDd7N{m2
HCC1419 M4nzUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jLfVEh|ryP MlTBOUBl NIW4UIxFVVOR NXnm[ZVTUUN3MEyxJO69VQ>? MYCyOFg4QTd7Nh?=
UACC-812 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\DUIxDOSEQvF2= NVS1Znp5PSCm MnjlSG1UVw>? MUPJR|UxRDFizszN MU[yOFg4QTd7Nh?=
HCC1187 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfTNUDPxE1? M1rsUVUh\A>? M{PxZ2ROW09? M{DJOWlEPTB:MTFOwG0> MkC3NlQ5Pzl5OU[=
KPL-1 NF7OUWNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVexJO69VQ>? NVr1[XJWPSCm Mlm2SG1UVw>? NWDTV49DUUN3MEyxJO69VQ>? MYqyOFg4QTd7Nh?=
SUM-225 NInrZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjZNlIyKM7:TR?= MkPvOUBl MoLJSG1UVw>? MX7JR|UxRDFizszN Ml35NlQ5Pzl5OU[=
EFM-192A NXHnVWFTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jPeVEh|ryP NX;2bIhKPSCm MWnEUXNQ MkfZTWM2ODxzIN88US=> MWCyOFg4QTd7Nh?=
JIMT-1 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2f5PVEh|ryP Ml3rOUBl NELvTVdFVVOR MUnJR|UxRDFizszN MWCyOFg4QTd7Nh?=
HCC1143 MkPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn30NUDPxE1? MUS1JIQ> NY\teVlCTE2VTx?= MV3JR|UxRDFizszN M2HweVI1QDd7N{m2
HCC2218 M{j4Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYSxJO69VQ>? NV;BfYdHPSCm NVPBPZdUTE2VTx?= M2fQbmlEPTB:MTFOwG0> NFzYdI0zPDh5OUe5Oi=>
MDA-MB-468 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWqxJO69VQ>? MkLDOUBl Mo\BSG1UVw>? MmjhTWM2ODxzIN88US=> NH\aNogzPDh5OUe5Oi=>
BT-20 NY\rPWpxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M173TlEh|ryP M13LdVUh\A>? M3:yUWROW09? NWnzWY03UUN3MEyxJO69VQ>? M3P0SlI1QDd7N{m2
MDA-MB-435 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqR5lWOSEQvF2= MoXrOUBl M2HYW2ROW09? NUDnNHVGUUN3MEyxJO69VQ>? MVWyOFg4QTd7Nh?=
BT-549 MkHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ixVlEh|ryP MmDUOUBl NXzYT4pyTE2VTx?= M{fSd2lEPTB:MTFOwG0> MWqyOFg4QTd7Nh?=
HCC1806 M3;3Xmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3ibJBxOSEQvF2= NYnjflBkPSCm NHXXUlhFVVOR MX3JR|UxRDFizszN NWT3fml7OjR6N{m3PVY>
HCC1937 M4PPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fIN|Eh|ryP MWK1JIQ> M2HVVmROW09? NIq4fIdKSzVyPEGg{txO MX6yOFg4QTd7Nh?=
Hs578T MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVSxJO69VQ>? MlHZOUBl MVvEUXNQ MWXJR|UxRDFizszN NX:5TnRmOjR6N{m3PVY>
LN18 M4ny[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7DV4YzOCEQvF2= NELYfpk4OiCq NHnqRphFVVOR M2XUeWlEPTB:NTFOwG0> MmTNNlQ4PDFyN{S=
LN229 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ZNlAh|ryP MoTUO|IhcA>? NYfPc3NqTE2VTx?= NUfPRnRNUUN3MEy1JO69VQ>? M{GyelI1PzRzMEe0
LNZ308 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXWyNEDPxE1? M{LPdVczKGh? MnnxSG1UVw>? MkPJTWM2ODx3IN88US=> M3nWelI1PzRzMEe0
T98G MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml65NlAh|ryP NH;Tb4Y4OiCq M2T5XWROW09? MXLJR|UxRDVizszN MomyNlQ4PDFyN{S=
U87 NGO1PGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TubFIxKM7:TR?= NHz4N3k4OiCq M{jy[WROW09? NIXNO2ZKSzVyPEWg{txO M1;1WFI1PzRzMEe0
LN18 NGD1eolHfW6ldHnvckBCe3OjeR?= NXftSoo6PSEQvF2= MXyyOEBp Ml6wSG1UVw>? NYnIPJdXUW6qaXLpeJMheGixc4Doc5J6dGG2aX;uJI9nKEGNVB?= NEHIem4zPDd2MUC3OC=>
LNZ308 MVnGeY5kfGmxbjDBd5NigQ>? MmW4OUDPxE1? M3fvRVI1KGh? M1n2S2ROW09? NIPmTWNKdmirYnn0d{BxcG:|cHjvdplt[XSrb36gc4YhSUuW NGTXdlgzPDd2MUC3OC=>
Saos-2 MoDFSpVv[3Srb36gRZN{[Xl? NUnoOWx{PTBizszN MUK0PEBp NHKzdVFKdmirYnn0d{Bk\WyuIHnueoF{cW:w M2e5PVI1PzJ5Nk[w
MG-63 M3;rUmZ2dmO2aX;uJGF{e2G7 MWG1NEDPxE1? NFTze3Y1QCCq MX;Jcohq[mm2czDj[YxtKGmwdnHzbY9v NYHHNpNPOjR5Mke2OlA>
SJSA-1 NVvLVGM4TnWwY4Tpc44hSXO|YYm= MoX3OVAh|ryP NH7IdWQ1QCCq MnXYTY5pcWKrdIOgZ4VtdCCrbo\hd4lwdg>? MnHpNlQ4Ojd4NkC=
Saos-2 M320WmZ2dmO2aX;uJGF{e2G7 MoDtOVAh|ryP NHK4d4M1QCCq MXrJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u NV7keVJ{OjR5Mke2OlA>
MG-63 MljBSpVv[3Srb36gRZN{[Xl? NWP2UnY4PTBizszN MVK0PEBp MWPJcohq[mm2czDtZZRzcXhibXX0ZYxtd3C{b4TlbY5ie2VvMjDlfJBz\XO|aX;u Mlz0NlQ4Ojd4NkC=
SJSA-1 NYLBOGozTnWwY4Tpc44hSXO|YYm= M2TH[FUxKM7:TR?= MlnoOFghcA>? M1PDOGlvcGmkaYTzJI1ifHKreDDt[ZRidGyxcILveIVqdmG|ZT2yJIV5eHKnc4Ppc44> NHjtbYwzPDd{N{[2NC=>
Saos-2 MnWzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXYblFtPTBizszN MVS0PEBp NYDHNGV5UW6qaXLpeJMh[2WubDD2bYFjcWyrdIm= MofUNlQ4Ojd4NkC=
MG-63 NUO3cpNST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV[1NEDPxE1? NWXSS2JNPDhiaB?= NEDBfHlKdmirYnn0d{Bk\WyuII\pZYJqdGm2eR?= Mo[0NlQ4Ojd4NkC=
SJSA-1 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWL4enZWPTBizszN NGi5OXg1QCCq Mm[yTY5pcWKrdIOgZ4VtdCC4aXHibYxqfHl? MoDiNlQ4Ojd4NkC=
FaDu MoroSpVv[3Srb36gRZN{[Xl? NULHRpdGPSEQvF2= MVqyOEBp NWfLbm9PTE2VTx?= MnfPVoVlfWOnczDvfJlo\W5iY3;ud5VueHSrb36= NGHicnEzPDZ|MUG0Oy=>
EMT6 MVjGeY5kfGmxbjDBd5NigQ>? MWe1JO69VQ>? MYOyOEBp NUO0NpBNTE2VTx?= NYjXXHpGWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> MkTBNlQ3OzFzNEe=
HCT116 NFrxUGlHfW6ldHnvckBCe3OjeR?= NI\CTYE2KM7:TR?= MUiyOEBp MlHySG1UVw>? NWDDOVNWWmWmdXPld{BwgHmpZX6gZ49ve3WvcITpc44> M2j1[lI1PjNzMUS3
U87 MUjGeY5kfGmxbjDBd5NigQ>? NIDHV4o2KM7:TR?= NYjUVnRrOjRiaB?= NELyO21FVVOR M1zXVHJm\HWlZYOgc5h6\2WwIHPvcpN2dXC2aX;u NIrCOpEzPDZ|MUG0Oy=>
GBM NWnJTVN[SXCxcITvd4l{KEG|c3H5 NI\jNpEz|ryP NXvFV4djPDiq NW\4R4JPTE2VTx?= Mom4bY5lfWOnZDDobYdp\XJibHX2[Yx{KG:oIHHwc5B1d3OrczygZY5lKGSnY4LlZZNm\CClZXzsJJZq[WKrbHn0fS=> MYeyOFUxODR7Mh?=
BON MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWWxMVXPxE1? MVW3Nog> NG\H[WVl\WO{ZXHz[ZMh[2WubDDwdo9tcW[ncnH0bY9v M{jsU|I1PDR|NUKz
BON MVTBdI9xfG:|aYOgRZN{[Xl? M{XYXlEuPc7:TR?= M13OOFI1cA>? MmnIbY5kemWjc3XzJIFxd3C2b4Ppdy=> MmXUNlQ1PDN3MkO=
H1975 MoTtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHvN[lkxNjNvOT62{txO M37vPVczcA>? NV;3fIN6TE2VTx?= M1LoOGlEPTB;MT6zPFXPxE1? NFLOc4szPDN|N{i0Oi=>
H1975 MWDBdI9xfG:|aYOgRZN{[Xl? NXTtdZBMOs7:TR?= MV:yOIg> M2LCRmROW09? MofHbY5kemWjc3XzJIFxd3C2b4Ppd{Bz[XSnIIPp[45q\mmlYX70cJk> MX2yOFM{Pzh2Nh?=
T-ALL NUPIbI52SXCxcITvd4l{KEG|c3H5 MmDIZoV1f2WnbjCxMlQh[W6mIEWuN{BuVSCjdDCyOIgh[W6mIECuPUBidmRiNT61JI1OKGG2IES4bEBqdiCmaX\m[ZJmdnRiY3XscEBtcW6n MnLMNlQhd3JiNEjo NEOycFNFVVOR NIXDdYZi\m[nY4TzJJRp\SCSSUPLJJBifGi5YYmgbY4hXC2DTFygZ4VtdCCuaX7ldy=> M4nTcFI1OzFyN{O2
BCR-ABL MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVXKc2lvOC5{NT2xNO69VQ>? MX[0[C=> M4XjdpNq\26rZnnjZY51dHliaX7obYJqfCClZXzsJJBzd2yrZnXyZZRqd25? MXqyOFI1PDZzMh?=
LC-1/SQSF NEHWZWdHfW6ldHnvckBCe3OjeR?= NWLTeVhmO87:TR?= M4K4dlI1cA>? NGS2bYNFVVOR NEPBUpRl\WO{ZXHz[UBPWkZ{IIDyc5RmcW5ibHX2[Yw> NGHa[FAzOzl6MEC5Ny=>
Primary CLL cells M4LnRmFxd3C2b4Ppd{BCe3OjeR?= NIP3boQyNTFyzszN NW\4d5J3PDiq MYDpcoR2[2W|IHHwc5B1d3OrczDpckBEVExiY3XscJMhcW6mZYDlcoRmdnRib3[gdJJw\26xc4TpZ{Bu[XKtZYLz NHfFXoczOzh3MEiwOy=>
Primary CLL cells NXT5ZXhqU2mwYYPlJGF{e2G7 MoXQNu69VQ>? M4CwfFMxdWmw MoTB[IVkemWjc3XkJHBKO0tiYXP0bZZqfHl? NUfQeXoyOjN6NUC4NFc>
Primary CLL cells NXv5S2p4S3m2b4TvfIlkKEG|c3H5 MoPJNu69VQ>? M4\BPFI1cA>? NYTrbHpPcW6mdXPld{Bk\WyuIHP5eI91d3irY3n0fS=> NYS5V|k5OjN6NUC4NFc>
human NSCLC cell lines MlnSRZBweHSxc3nzJGF{e2G7 NIfJO5cxNjF{NT20{txO Mm\INlRp MYjEUXNQ NWT1N2NxUUN3MIOgdoFv\2W|IH\yc40hOC52LUNOwG0> MWWyN|U3OjR5Mh?=
human HCC cell lines NIjZeVVE\WyuII\pZYJqdGm2eTDhd5NigQ>? NWjWdnZZOC5yMEWtNe69VQ>? M3\mdVQ5cA>? M2PKNWlEPTB;Md88US=> MYmyN|Q5QTl7OR?=
Huh7 NVrRe4N6U2mwYYPlJGF{e2G7 NIPj[|My|ryP NIjNblY1QGh? MnPHd4lodmoxrJHjZY51dHlicnXkeYNmeyCyaH;zdIhwenmuYYTpc44hd2ZiQXv0 MW[yN|Q5QTl7OR?=
SK-HEP1 NVTqXWhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4nET|EuOjEQvF2= MUS3Nog> NF7lbmdFVVOR NYWyblVUUUN3MP-8oFHPxE1? MYGyN|Q4QTF|Nh?=
786-0 M4HsZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGnhbZoyNTJyzszN M3jxUlczcA>? NUL1NXhnTE2VTx?= M4jadWlEPTExvKyx{txO NGLoOmwzOzR5OUGzOi=>
JVM2 M{P3WWN6fG:2b4jpZ4l1gSCjc4PhfS=> MXuwMlIuOjEQvF2= Ml7XO|Jp MUfEUXNQ Mlq1TWM2OD1yLkpOwG0> MoD2NlMzOzh4M{m=
EHEB NYTBS2xiS3m2b4TvfIlkcXS7IHHzd4F6 MV:wMlIuOjEQvF2= MYO3Nog> NXnHWFl{TE2VTx?= Mn32TWM2OD1yLkhOwG0> NH[zSZYzOzJ|OE[zPS=>
MEC2 M4PuRWN6fG:2b4jpZ4l1gSCjc4PhfS=> M2\kZ|AvOi1{MN88US=> NF3Ycng4Omh? NXTZZVdDTE2VTx?= NYrMbnpvUUN3ME2wMlfPxE1? M3Kxe|I{OjN6NkO5
primary B-CLL lymphocytes Mkf3RZBweHSxc3nzJGF{e2G7 NFP1cWpKSzVyIH\vdkBm[WOqIIDybY1ienliY3XscEBtcW6n Mnf5NlRp MXrEUXNQ MYXJR|Ux97zeM988UUBnd3JiYXzsJJBifGmnboTz MViyN|I{QDZ|OR?=
primary B-CLL lymphocytes M2O0cmtqdmG|ZTDBd5NigQ>? NXXwbpRNUUN3MDDmc5Ih\WGlaDDwdolu[XK7IHPlcIwhdGmwZR?= MVKyOIg> NVuzfld{cW6qaXLpeJMheDdyU{\LJEYhPEVvQmCxJIV5eHKnc4Ppc44> MWSyN|I{QDZ|OR?=
human NSCLC NULhZmc4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M130[VAvPS1{zszN MWK3Nog> NX7GOVNxUUN3ME2x{txO Mm\pNlI4QDF|OUO=
human NSCLC M1vYO2tqdmG|ZTDBd5NigQ>? Ml:yNe69VQ>? NYXBSoZPOjSq NHnHSIVqdmirYnn0d{B1cGViQXv0M41VV1Jic3nncoFtcW6pIIDheIh4[XliYYSgN4gh[W[2ZYKgeJJm[XSvZX70 MmPWNlI4QDF|OUO=
Y1 cell line Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVewMlHPxE1xMd88US=> Ml\6NlRp NGXVVYxFVVOR NUXPU5RtcW6qaXLpeJMhPjExvJWgZ4VtdCC4aXHibYxqfHliaX6gUZlkNVOldIKteJJidnOoZXP0[YQh[2WubIO= MoHJNlI3QTJ7MES=
PIK3CA-mutant MCF7 NYflR2N4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGT3[WZIUTVyPUG2NOKyQTGwTf-8kGxFPTB;OUiwxtEzPzOwTR?= MVK3Nog> NVLvNJlZT0l3ME2xOlDDuTlzbl5vwKxNTDVyPUm4NOKyOjd|bl2= M3TQdFIzPjV|OU[3
PIK3CA-mutant MCF7 Ml;lT4lv[XOnIFHzd4F6 MlWxTWM2OD1zMUVCtVNvVQ>? Mn3tO|Jp NEjvb5FKSzVyPUGxOOKyO26PIHnuJJJm\HWlaX7nJGFsfCCyaH;zdIhwenmuYYTpc44hdGW4ZXzz M4DXXlIzPjV|OU[3
MCF7-myr-Akt MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH:wUGdIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= NH\GZpo4Omh? NH23elhIUTVyPUK5PeKyPjiwTf-8kGxFPTExvK6xNEwxODCwTR?= M4Szd|IzPjV|OU[3
colon cancer cell lines MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnL6NE0yOM7:TR?= MXq3Nog> MWXEUXNQ MlmwTWM2OD1zzszN NHjZeZkzOjV2M{i1Oy=>
gastric cancer cell lines NGG4e4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom2NE0yOM7:TR?= NIP5TJY4Omh? Ml\CSG1UVw>? M2[5WWlEPTB;Mj21{txO NWXaXFV[OjJ3NEO4OVc>
HCT-116/HT-29/MKN-45 MWXBdI9xfG:|aYOgRZN{[Xl? NGqzO5kz|ryP MUm0PIg> NIDoRZd{cGmodDDpckBIOiCyaHHz[S=> MVSyNlU1Ozh3Nx?=
HT-29 and HCT-116 MYXDZZNx[XOnIHHzd4F6 MoW2Oe69VQ>? NXX1NVM2OjSq NEjWWnNqdmS3Y3XzJINie3Cjc3WgZYN1cX[rdIm= NYeyO4E2OjJ3NEO4OVc>
MM cell lines MljCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{LPT|Ex|ryP NVjxVYpiOjSq MkDUSG1UVw>? MnzyTWM2OCC4YYLp[ZMh[W2xbneg[Iln\mW{ZX70JINmdGxibHnu[ZMhcW5idHnt[UBidmRiZH;z[UBl\XCnbnTlcoNm NVfBRWozOjJ{MEe0PFU>
ARP-1 NHLoNVRCeG:ydH;zbZMhSXO|YYm= M{fJXFEx|ryP NFzxcVUzPGh? M3T5XmROW09? MYnpcoR2[2W|IF3NJINmdGxiYYDvdJRwe2m|IITodo92\2hiY3HzdIF{\SCjY4TpeoF1cW:w NI\rfngzOjJyN{S4OS=>
SNU-601 MmD3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXK3Nog> Moj0SG1UVw>? MU\JR|UxRTBwOEG2xtExNjB4M988US=> MV6yNlE2QThzNB?=
SNU-1 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2LiXVczcA>? Mn70SG1UVw>? MlnTTWM2OD1zLkC4NuKyOC5yMklOwG0> MmixNlIyPTl6MUS=
SNU-668 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWW3Nog> NWLhRYdxTE2VTx?= MWjJR|UxRTFwNUe5xtExNjB5NN88US=> Mn:4NlIyPTl6MUS=
AGS M{jWWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{nkblczcA>? NVXnfI5kTE2VTx?= NXHXRZpDUUN3ME2xMlcyPMLzMD6xNVfPxE1? NWjqbotOOjJzNUm4NVQ>
SNU-216 M3nYNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIf2fVY4Omh? NYXXTZhNTE2VTx?= MXHJR|UxRTJwNkmyxtExNjB6Mt88US=> NX7vc5lQOjJzNUm4NVQ>
SNU-5 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTCO|Jp NFzrXnZFVVOR M4jCd2lEPTB;MT6zOVHDuTBwMEmx{txO NELjZoYzOjF3OUixOC=>
SNU-638 NX;wdHg{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUD5dWV6PzKq MW\EUXNQ Ml31TWM2OD1{LkK4NuKyOC5yNUROwG0> Ml3CNlIyPTl6MUS=
SNU-16 M3j6UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXO3Nog> MYfEUXNQ NVnYeoRQUUN3ME2xMlU4O8LzMD6wNFHPxE1? NEmyZnkzOjF3OUixOC=>
SNU-484 M4jFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nGZlczcA>? NGS2fWZFVVOR NHLUc25KSzVyPUGuO|I5yrFyLkC0Oe69VQ>? MojsNlIyPTl6MUS=
SNU-620 M3XP[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vOPFczcA>? NXXhSFJ3TE2VTx?= NHnEcYxKSzVyPUKuPVM6yrFyLkCwNe69VQ>? MVWyNlE2QThzNB?=
SNU-719 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe3Nog> NFzSUINFVVOR MV\JR|UxRTNwMEO3xtExNjB|Mt88US=> M2O5N|IzOTV7OEG0
glioma cell lines NFL6XHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYG3Nog> M3TKTWlEPTB;MT2y{txO M3[yd|IzODZ3MEiw
U87 MnfJRZBweHSxc3nzJGF{e2G7 MoXvNu69VQ>? MYe3Nog> NH3mZ2ZqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHHu[EBkdGWjdnXkJHBCWlBiYX7kJINie3Cjc3WtNy=> M2j6[lIzODZ3MEiw

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western blot
p-AKT (T308) / p-AKT (S473) / AKT; 

PubMed: 27283525     


Left western blots showing levels of pAkt (T308), pAkt (S473) and total Akt in U87 cells exposed to buparlisib for 72 h. Right densitometric assessment of western blots, showing relative changes in phosphorylation.

p-FOXO3a (S253) / FOXO3a; 

PubMed: 28036259     


Cells were treated with 0.5 μM BKM120 for 24 h and cell lysates were immunoblotted with the indicated antibodies. Actin was used as the loading control.

Nuclear NF-κB p65 / NF-κB p65; 

PubMed: 26673665     


Western blots show BKM120 downregulating pAKT, nuclear NF-κB p65 and total NF-κB p65 in MDR and their parental cells. β-actin was used as a loading control for pAKT, AKT and total NF-κB p65. Lamin B was used as a loading control for nuclear NF-κB p65. 

p-ERK / ERK / LC3; 

PubMed: 27572309     


The indicated cell lines were exposed to different concentrations of BKM120 as indicated for 8 h A. or with 2 μM BKM120 for the indicated times B. The cells were then harvested for preparation of whole-cell protein lysates and subsequent Western blot analysis to detect the given proteins.

p-STAT3 / STAT3 / p-ERK / ERK / p-S6; 

PubMed: 29928341     


Western blot analysis of H460 and H2126 cell lysates using specific antibodies to phosphorylated or total proteins of STAT3, ERK1/2, AKT, S6 or GAPDH (loading control). The cells were treated with increasing concentrations of BKM120 for 24 h.

p-MET / MET; 

PubMed: 29928341     


The expression of phosphorylated or total forms of MET protein was analyzed by western blotting. 

27283525 28036259 26673665 27572309 29928341
Immunofluorescence
FOXO3a; 

PubMed: 28036259     


Cells were cultured on coverslips to approximately 60% confluency and then treated with 1 μM BKM120 for an additional 24 h. Immunofluorescence staining was performed using an anti-FOXO3a antibody and the nuclei were stained with DAPI. Scale bar, 20 μm.

28036259
Growth inhibition assay
Cell viability; 

PubMed: 26673665     


Dose-response curves were used to calculate the IC50 of BKM120 for MCs of MCF-7/A02 cells (upper) and CALDOX cells (lower).

26673665
体内研究 BKM120按30, 60, 或100 mg/kg剂量作用于A2780移植瘤,完全抑制pAKTser473。BKM120按 30和 60 mg/kg剂量作用于U87MG神经胶质瘤模型,显示抗癌活性。[1]BKM120每天按5μM/kg剂量处理具有持久生命力的ARP1 SCID鼠模型,导致肿瘤体积和K链水平明显降低。[2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[2]
- 合并

PI3K 生化实验(ATP 消耗实验):

BKM120溶于DMSO中,按每孔1.25 µL直接加到黑色384孔板上。开始反应, 25 µL 10nM PI3K和5 µg/mL 1-α-磷酸肌醇(PI)加到实验 buffer (10 mM Tris pH 为7.5, 5 mM MgCl2, 20 mM NaCl, 1 mM DTT,及0.05% CHAPS),然后加到每孔中,随后在实验buffer中加入25 µL 2 µM ATP。反应进行直到50% ATP被消耗,然后加入25 µL KinaseGlo溶液终止反应。终止的反应温育5分钟,然后通过荧光测定残留的ATP。
细胞实验:[1]
- 合并
  • Cell lines: A2780细 胞
  • Concentrations: 0-6.6 μM
  • Incubation Time: 3天
  • Method: A2780细胞培养在含10% FBS,L-谷氨酸,丙酮酸钠和抗生素的DMEM培养基上。细胞按每孔103个细胞的密度接种在相同培养基上,温育3到5小时。稀释溶于20 mM DMSO中的BKM120。2 µL稀释的BKM120溶液加到细胞培养基上, (浓度为0-6.6 µM)。等体积(100 µL)溶液加到96孔板中,在37oC下温育3天。使用Trilux读取荧光值而测定抑制细胞增殖的效果
    (Only for Reference)
动物实验:[1]
- 合并
  • Animal Models: 携带U87MG 和A2780移植瘤的雌性裸鼠
  • Dosages: ~60 mg/kg
  • Administration: 每天口服处理
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 82 mg/mL (199.8 mM)
Water Insoluble
Ethanol '2 mg/mL
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
5% DMSO+30% PEG 300+ddH2O
15mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 410.39
化学式

C18H21F3N6O2

CAS号 944396-07-0
储存条件 粉状
溶于溶剂
别名 NVP-BKM120

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % ddH2O
计算重置

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04338399 Not yet recruiting Drug: Buparlisib & Paclitaxel Head and Neck Cancer Adlai Nortye Biopharma Co. Ltd. July 31 2020 Phase 3
NCT02614508 Terminated Drug: Buparlisib|Drug: Ibrutinib|Biological: Ofatumumab Recurrent Chronic Lymphocytic Leukemia|Recurrent Small Lymphocytic Lymphoma|Refractory Chronic Lymphocytic Leukemia|Refractory Small Lymphocytic Lymphoma Emory University|Novartis January 2016 Phase 1
NCT01613677 Withdrawn Drug: BKM120 Treatment for Metastatic or Locally Advanced Cervical Cancer Novartis Pharmaceuticals|Novartis November 2015 Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

相关PI3K产品

Tags: 购买Buparlisib (BKM120) | Buparlisib (BKM120)供应商 | 采购Buparlisib (BKM120) | Buparlisib (BKM120)价格 | Buparlisib (BKM120)生产 | 订购Buparlisib (BKM120) | Buparlisib (BKM120)代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID